```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page for STN Seminar Schedule - N. America
 NEWS  2  DEC 01   ChemPort single article sales feature unavailable
 NEWS  3  JUN 01   CAS REGISTRY Source of Registration (SR) searching
                   enhanced on STN
 NEWS  4  JUN 26   NUTRACEUT and PHARMAML no longer updated
 NEWS  5  JUN 29   IMSCOPROFILE now reloaded monthly
 NEWS  6  JUN 29   EPFULL adds Simultaneous Left and Right Truncation
                   (SLART) to AB, MCLM, and TI fields
 NEWS  7  JUL 09   PATDPAFULL adds Simultaneous Left and Right
                   Truncation (SLART) to AB, CLM, MCLM, and TI fields
 NEWS  8  JUL 14   USGENE enhances coverage of patent sequence location
                   (PSL) data
 NEWS  9  JUL 27   CA/CAplus enhanced with new citing references
 NEWS 10  JUL 16   GBFULL adds patent backfile data to 1855
 NEWS 11  JUL 21   USGENE adds bibliographic and sequence information
 NEWS 12  JUL 28   EPFULL adds first-page images and applicant-cited
                   references
 NEWS 13  JUL 28   INPADOCDB and INPAFAMDB add Russian legal status data
 NEWS 14  AUG 10   Time limit for inactive STN sessions doubles to 40
                   minutes
 NEWS 15  AUG 18   COMPENDEX indexing changed for the Corporate Source
                   (CS) field
 NEWS 16  AUG 24   ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
 NEWS 17  AUG 24   CA/CAplus enhanced with legal status information for
                   U.S. patents
 NEWS 18  SEP 09   50 Millionth Unique Chemical Substance Recorded in
                   CAS REGISTRY
 NEWS 19  SEP 11   WPIDS, WPINDEX, and WPIX now include Japanese FTERM
                   thesaurus

 NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
              AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:06:05 ON 23 SEP 2009

=> file reg
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 16:06:26 ON 23 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
```

provided by InfoChem.

STRUCTURE FILE UPDATES: 22 SEP 2009 HIGHEST RN 1186072-05-8
DICTIONARY FILE UPDATES: 22 SEP 2009 HIGHEST RN 1186072-05-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10531783-broad.str

L1   STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1   STR



G1 Me,Et,n-Pr,i-Pr

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 16:06:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   6241 TO ITERATE

 32.0% PROCESSED   2000 ITERATIONS   4 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 120083 TO   129557
PROJECTED ANSWERS: 38 TO   460

L2   4 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 16:06:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   126827 TO ITERATE

100.0% PROCESSED 126827 ITERATIONS 248 ANSWERS
SEARCH TIME: 00.00.03

L3 248 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 186.36 186.58

FILE 'CAPLUS' ENTERED AT 16:07:33 ON 23 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 23 Sep 2009 VOL 151 ISS 13
FILE LAST UPDATED: 22 Sep 2009 (20090922/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family
of databases have been updated to include new citing references
information. This enhancement may impact record import into
database management software. For additional information, refer
to NEWS 9.

=> s l3
L4 127 L3

=> s l4 py not > 2003
MISSING OPERATOR L4 PY
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l4 not py > 2003
  7813375 PY > 2003
L5 82 L4 NOT PY > 2003

=> s l5 and ligand
  374492 LIGAND
L6 0 L5 AND LIGAND

```
=> s l5 and affinity
        335097 AFFINITY
L7           1 L5 AND AFFINITY

=> s l5 and support
        579048 SUPPORT
L8           0 L5 AND SUPPORT

=> s l5 and solid
       1221171 SOLID
L9           2 L5 AND SOLID

=> s l5 and Fab
         19564 FAB
L10          0 L5 AND FAB

=> s l5 and IgG
         86381 IGG
L11          0 L5 AND IGG

=> s l5 and human
       2261058 HUMAN
L12          2 L5 AND HUMAN

=> s l5 and chromatography
        358201 CHROMATOGRAPHY
L13          0 L5 AND CHROMATOGRAPHY

=> s l5 and column
        470328 COLUMN
L14          0 L5 AND COLUMN

=> s l5 and matrix
        622387 MATRIX
L15          0 L5 AND MATRIX

=> s l5 and immunology
          6097 IMMUNOLOGY
L16          0 L5 AND IMMUNOLOGY

=> s l7 or l9 or l12
L17          5 L7 OR L9 OR L12

=> d l17 ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):y

L17  ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:        2002:449646  CAPLUS
DOCUMENT NUMBER:         137:33211
TITLE:                   Preparation of N-indolylurea derivatives as peroxisome
                         proliferator activated receptor δ (PPAR δ)
                         activators
INVENTOR(S):             Takahashi, Toshihiro; Sakuma, Shogo; Endo, Tsuyoshi;
                         Tendo, Atsushi; Yoshida, Shinichi; Kobayashi, Kunio;
                         Mochiduki, Nobutaka; Yamakawa, Tomio; Kanda, Takashi;
                         Masui, Seiichiro
PATENT ASSIGNEE(S):      Nippon Chemiphar Co., Ltd., Japan
SOURCE:                  PCT Int. Appl., 81 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                Japanese
FAMILY ACC. NUM. COUNT:  1
```

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046154	A1	20020613	WO 2001-JP10576	20011204
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002024138	A	20020618	AU 2002-24138	20011204
PRIORITY APPLN. INFO.:			JP 2000-369890 A	20001205
			WO 2001-JP10576 W	20011204

OTHER SOURCE(S): MARPAT 137:33211

GI



I

AB Urea derivs. represented by the general formula (I) or salts thereof [wherein Y = O, S; n = an integer of 0-4; R4, R5 = H, C1-8 alkyl optionally substituted by 1-3 of halogen atoms; W = CO2H, C2-8 alkoxycarbonyl, SO3H, cyano, tetrazolyl; a solid line accompanied by a dotted line represents a single or double bond; one of Ra, Rb, and Rc is R1N(R2)CON(R3)X and the other two groups are H, C1-8 alkyl, C6-10 aryl, C1-8 alkyl-C6-10 aryl; wherein R1, R2, R3 = H, C1-8 alkyl optionally substituted by 1-3 of halogen atoms, C1-8 alkoxy-C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-8 alkyl, C6-10 aryl, C6-10 aryl-C1-8 alkyl, heterocyclyl, heterocyclyl-C1-8 alkyl; X = C1-8 alkylene, remaining two R8 and R9 are each hydrogen or C1-8 alkyl; aryl, heterocyclyl, or aryl or heterocyclyl of arylalkyl or heterocyclylalkyl group is optionally substituted in Ra, Rb, and Rc] are prepared These compds. are useful as blood sugar-lowering agents, hypolipidemics, antiobesity agents, hypocholesteremics, antiarteriosclerotics, anticancer agents, antiinflammatory agents, etc. Thus, 47 mg 2,4-dichlorophenyl isocyanate was added to a solution of 78 mg 2-[[1-[2-(isobutylamino)ethyl]indol-5-yl]oxy]-2-methylpropionic acid Et ester in EtOAc and stirred at room temperature for 0.5 h to give 83% 2-[[1-[2-(N'-2,4-dichlorophenyl-N-isobutylamino)ethyl]indol-5-yl]oxy]-2-methylpropionic acid Et ester which (96 mg) was dissolved in ethanol, treated with 1 M aqueous NaOH, stirred at room temperature for 16 h, treated with 0.1 M aqueous HCl under ice-cooling, and stirred at room temperature for 1 h to give 100% 2-[[1-[2-(N'-2,4-dichlorophenyl-N-isobutylureido)ethyl]indol-5-yl]oxy]-2-methylpropionic acid (II). In an assay for activating effect of PPARδ receptor using CV-1 cells transfected with PPARδ receptor-expressing plasmid, luciferase-expressing plasmid, and β-galactosidase-expressing plasmid, II at 10-5 M exhibited 106% activation compared to L-165041.

IT 435277-48-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-indolylurea derivs. as peroxisome proliferator activated receptor δ (PPAR δ) activators for drugs)

RN 435277-48-8 CAPLUS

CN Propanoic acid, 2-[[1-[2-[[[(2,4-dichlorophenyl)methylamino]carbonyl](2-methylpropyl)amino]ethyl]-1H-indol-5-yl]oxy]-2-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:175776 CAPLUS

DOCUMENT NUMBER: 137:279130

TITLE: Identification of a novel, orally bioavailable histamine H3 receptor antagonist based on the 4-benzyl-(1H-imidazol-4-yl) template

AUTHOR(S): Aslanian, Robert; Mutahi, Mwangi W.; Shih, Neng-Yang; McCormick, Kevin D.; Piwinski, John J.; Ting, Pauline C.; Albanese, Margaret M.; Berlin, Michael Y.; Zhu, Xiaohong; Wong, Shing-Chun; Rosenblum, Stuart B.; Jiang, Yueheng; West, Robert; She, Susan; Williams, Shirley M.; Bryant, Matthew; Hey, John A.

CORPORATE SOURCE: The Schering Plough Research Institute, Kenilworth, NJ, 07033, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(6), 937-941
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:279130

GI



I

AB A novel series of histamine H3 receptor antagonists, based on the 4-benzyl-(1H-imidazole-4-yl) template, incorporating urea and carbamate linkers has been prepared The urea I is a selective H3 antagonist and demonstrates excellent oral plasma levels in the rat and monkey.

IT 466671-37-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of imidiazolylmethylbenzylureas as histamine H3 receptor antagonists)
RN 466671-37-4 CAPLUS
CN Urea, N-(3,5-dichlorophenyl)-N,N'-dimethyl-N'-[[4-[[1-(triphenylmethyl)-1H-imidazol-4-yl]methyl]phenyl]methyl]- (CA INDEX NAME)



IT 705264-28-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of imidiazolylmethylbenzylureas as histamine H3 receptor antagonists)
RN 705264-28-4 CAPLUS
CN Urea, N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-5-ylmethyl)phenyl]methyl]-N,N'-dimethyl- (CA INDEX NAME)



OS.CITING REF COUNT: 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS RECORD (24 CITINGS)
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:237842 CAPLUS
DOCUMENT NUMBER: 134:266205
TITLE: Preparation of collagen formation-inhibiting benzene derivatives
INVENTOR(S): Kojima, Hiroshi; Sakamoto, Makoto; Yasumura, Koichi
PATENT ASSIGNEE(S): Ohtsuka Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 97 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001089412	A	20010403	JP 1999-269015	19990922

PRIORITY APPLN. INFO.: JP 1999-269015 19990922
OTHER SOURCE(S): MARPAT 134:266205
AB (R1)aC6H5-aVBWA [I; R1 = H, halo, OH, NO2, cyano, etc.; a = 1-5; V = NHCO, CONH, NHCONH, NHC(S)NH, SCH2CONH, etc.; B = p-C6H4, (un)substituted pyridine-2,5-diyl, pyrimidine-2,5-diyl, pyrazine-2,5-diyl, pyridine-2,3-diyl; W = O, S, SO, NH, CO, CH2, SO2; A = aryl] or their salts, useful for treatment of lung or liver fibrosis, are prepared 3,4,5-Trimethoxybenzoic acid (440 mg) was amidated by 500 mg 3-amino-6-(4-tert-butylphenoxy)pyridine in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide.HCl and 1-hydroxybenzotriazole in DMF at room temperature for 1 day to give 750 mg I [(R1)a = 3,4,5-(OMe)3, V = CONH, B = pyridine-2,5-diyl, W = O, A = C6H4CMe3-p]. I [(R1)a = 3,4-Cl2, V = CONH, B = p-C6H4, W = O, A = 5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl] in vitro inhibited TGF β-1-induced collagen synthesis in human LI90 cells with IC50 of 2.37 μM.
IT 332009-21-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of collagen formation-inhibiting benzene derivs.)
RN 332009-21-9 CAPLUS
CN Urea, N-(3,4-dichlorophenyl)-N'-[6-[(2,3-dihydro-1-oxo-1H-inden-4-yl)oxy]-3-pyridinyl]-N-methyl- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:66714 CAPLUS
DOCUMENT NUMBER: 128:136098
ORIGINAL REFERENCE NO.: 128:26594h,26595a
TITLE: A Novel Class of Orally Active Non-Peptide Bradykinin B2 Receptor Antagonists. 1. Construction of the Basic Framework
AUTHOR(S): Abe, Yoshito; Kayakiri, Hiroshi; Satoh, Shigeki; Inoue, Takayuki; Sawada, Yuki; Imai, Keisuke; Inamura, Noriaki; Asano, Masayuki; Hatori, Chie; Katayama, Akira; Oku, Teruo; Tanaka, Hirokazu
CORPORATE SOURCE: Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ibaraki, 300-26, Japan
SOURCE: Journal of Medicinal Chemistry (1998), 41(4), 564-578
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A novel class of potent, selective, and orally active non-peptide bradykinin (BK) B2 receptor antagonists were designed and synthesized starting from 8-benzyloxyimidazo[1,2-a]pyridine derivative(I). The unique screening lead I was discovered by a 2-step intentional random screening process, involving recognition of the relationship between BK and angiotensin II (Ang II) and the common structural features. Systematic chemical modification of I elucidated the structural requirements essential for B2 binding affinity leading to the identification of 8-[[3-(N-acylglycyl-N-methylamino)-2,6-dichlorobenzyl]oxy]-3-halo-2-methylimidazo[1,2-a]pyridine skeleton as the basic framework of this new series of B2 antagonists. A mol. modeling study suggested the key role of the N-methylanilide moiety at the 3-position of the 2,6-dichlorobenzene ring to allow these compds. to adopt the characteristic active conformation. The representative lead compds. inhibited the specific binding of [3H]BK to guinea pig ileum membrane prepns. expressing B2 receptors, with nanomolar IC50s and also displayed in vivo functional antagonistic activities against BK-induced bronchoconstriction in guinea pigs at an oral dose of 1 mg/kg. Pharmacokinetic studies of the N-butylamide and Et urea moieties at the 3-position of the 2,6-dichlorobenzene in rats highlighted their excellent oral bioavailabilities, indicating that they represent the first orally active non-peptide B2 antagonists reported to date.

IT 160642-24-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and MSBAR of nonpeptide bradykinin B2 receptor antagonists)
RN 160642-24-0 CAPLUS
CN Urea, N-[3-[[(3-bromo-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]methyl]-2,4-dichlorophenyl]-N,N'-dimethyl- (CA INDEX NAME)



OS.CITING REF COUNT: 69 THERE ARE 69 CAPLUS RECORDS THAT CITE THIS RECORD (70 CITINGS)
REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1967:508325 CAPLUS
DOCUMENT NUMBER: 67:108325
ORIGINAL REFERENCE NO.: 67:20403a,20406a
TITLE: Tuberculostatic urea derivatives
INVENTOR(S): Gagneux, Andre R.; Frick, Wilhelm
PATENT ASSIGNEE(S): Geigy, J. R., A.-G.
SOURCE: Ger., 5 pp.
CODEN: GWXXAW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1246722		19670810	DE 1966-G48486	19661117
CH 456570			CH	
FR 1504098			FR	
FR 6433			FR	
GB 1125559			GB	
US 3539626		19701110	US	19681212
US 3621040		19710000	US	
US 3621100		19711116	US	19681118

PRIORITY APPLN. INFO.: CH 19651118

AB The title compds. are prepared by treating a) adamantylamines with an aryl isocyanate, aryl isothiocyanate, or a carbanilic or thiocarbanilic acid derivative; b) an adamantyl isocyanate, isothiocyanate, carbamate, or thiocarbamate with an aryl amine; or c) an adamantyl and aryl substituted carbodiimide with H2O or H2S. Thus, a mixture of 36.5 millimoles 1-adamantylamine in 100 ml. absolute C6H6 and 33.3 millimoles 3,4-dichlorophenyl isocyanate in 100 ml. absolute C6H6 is heated at 80° 1 hr. and cooled and the filtered solid stirred 1 hr. in 100 ml. N HCl to give 1-(1-adamantyl)-3-(3,4-dichlorophenyl)urea, m. 220-1°. Similarly prepared are the following substituted 1-(1-adamantyl)ureas (substituents and m.p. given): 3-(p-MeC6H4), 252-6°; 3-(p-ClC6H4), 242-3°; 3-(2,4-Cl2C6H3), 221-2°; 3-[6,3-Cl(F3C)C6H3], 233-4°; 3-(o-MeOC6H4), 234-6°; 3-(p-MeOC6H4), 235-8°; 3-[2,5(MeO)2C6H3], 240-2°; 3-(m-AcC6H4), 200-4°; 1-Me-3-(3,4-Cl2C6H3), 193-5°; 3-Me-3-(3,4-Cl2C6H3), 180-2°. Also prepared are

1-(1-adamantyl)thioureas: 3-(p-ClC6H4), 172-3°; 3-(2,4-Cl2C6H3), 181-3°; 3-[4,3-Cl(F3C)C6H3], 169-71°; and 3-(3,4-Cl2C6H3) (I), 189-92°. Similarly prepared are 1-(1-adamantylmethyl)-3-(3,4-dichlorophenyl)urea, m. 189-91°; 1-(α-methyl-1-adamantylmethyl)-3-(3,4-dichlorophenyl)urea, m. 195-8°; 1-(tricyclo[4.3.1.13,8]undec-3-yl)-3-(3,4-dichlorophenyl)urea, m. 233-6°; and 1-(2-oxaadamant-1-yl)-3-(3,4-dichlorophenyl)urea, m. 208-10°. To a mixture of 15 millimoles I in 600 ml. absolute dioxane is added 50 millimoles anhydrous MgSO4 and 120 millimoles PbO, the mixture stirred at 60° 15 hrs., cooled, and filtered, the filtrate taken to dryness in vacuo, the oily residue dissolved in 300 ml. pentane, the turbid solution filtered through C, and the filtrate concentrated to give 1-(1-adamantyl)-3-(3,4-dichlorophenyl)carbodiimide, m. 60-1° (pentane). A mixture of 50 millimoles bicyclo[3.3.1]nonane-3,7-dione and 50 millimoles PhCH2NH2 in 300 ml. tetrahydrofuran is refluxed 0.5 hr., cooled, and added with stirring to 100 millimoles LiAlH4 in 100 ml. absolute Et2O, the mixture stirred at 40° 6 hrs., 19 ml. N NaOH added with ice-cooling, the precipitate filtered off, the filtrate evaporated, the residue dissolved in 500 ml. Me2CO, and 5 ml. concentrated HCl added, to afford N-benzyl-2-oxaadamantylamine - HCl (II), m. 242-5°. A solution of 33 millimoles II in 100 ml. EtOH is hydrogenated with 50 atmospheric H in the presence of 2 g. 5% Pd-C at 100° 2 hrs., the mixture cooled and filtered, the filtrate evaporated, 25 ml. concentrated NaOH solution added to the residue, the mixture extracted with Et2O, the Et2O evaporated, and the residue sublimed at 60° and 0.1 mm. to yield 2-oxaadamantylamine, m. 148-54°; hydrochloride m. 280°.

IT 16192-94-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 16192-94-2 CAPLUS

CN Urea, N-(3,4-dichlorophenyl)-N-methyl-N'-tricyclo[3.3.1.13,7]dec-1-yl- (CA INDEX NAME)